Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin

References

• American Diabetes Association Standard of medical care in diabetes – 2013 Diabetes Care 2013 36 Suppl 1 S11 S66 23264422
   PubMed Web of Science ®Google Scholar
• Tahrani AA Bailey CJ Del Prato S Barnett AH Management of type 2 diabetes: new and future developments in treatment Lancet 2011 378 182 197 21705062
   PubMed Web of Science ®Google Scholar
• Phung OJ Scholle JM Talwar M Coleman CI Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes JAMA 2010 303 1410 1418 20388897
   PubMed Web of Science ®Google Scholar
• Gross JL Kramer CK Leitão CB Diabetes and Endocrinology Meta-analysis Group (DEMA) Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis Ann Intern Med 2011 154 672 679 21576535
   PubMed Web of Science ®Google Scholar
• Karagiannis T Paschos P Paletas K Matthews DR Tsapas A Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis BMJ 2012 344 e1369 22411919
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 2002 39 2 Suppl 1 S1 S266 11904577
   PubMed Web of Science ®Google Scholar
• Koro CE Lee BH Bowlin SJ Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States Clin Ther 2009 31 2608 2617 20110005
   PubMed Web of Science ®Google Scholar
• Thomas MC Weekes AJ Broadley OJ Cooper ME Mathew TH The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study) Med J Aust 2006 185 140 144 16893353
   PubMed Web of Science ®Google Scholar
• Penno G Solini A Bonora E Renal Insufficiency And Cardiovascular Events (RIACE) Study Group Clinical significance of nonalbuminuric renal impairment in type 2 diabetes J Hypertens 2011 29 1802 1809 21738053
   PubMed Web of Science ®Google Scholar
• Abe M Okada K Soma M Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice Curr Drug Metab 2011 12 57 69 21303332
   PubMed Web of Science ®Google Scholar
• Moen MF Zhan M Hsu VD Frequency of hypoglycemia and its significance in chronic kidney disease Clin J Am Soc Nephrol 2009 4 1121 1127 19423569
   PubMed Web of Science ®Google Scholar
• Shurraw S Hemmelgarn B Lin M Alberta Kidney Disease Network Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study Arch Intern Med 2011 171 1920 1927 22123800
   PubMedGoogle Scholar
• Lipska KJ Bailey CJ Inzucchi SE Use of metformin in the setting of mild-to-moderate renal insufficiency Diabetes Care 2011 34 1431 1437 21617112
   PubMed Web of Science ®Google Scholar
• Fonseca VA Incretin-based therapies in complex patients: practical implications and opportunities for maximizing clinical outcomes: a discussion with Dr Vivian A Fonseca Am J Med 2011 124 Suppl 1 S54 S61 21194580
   PubMed Web of Science ®Google Scholar
• Lee S Bilous R STARDUST – study of the treatment and prevalence of renal disease in UK diabetes mellitus type 2 patients Diabetologia 2011 54 Suppl 1 S128 A293
   Google Scholar
• He YL Clinical pharmacokinetics and pharmacodynamics of vildagliptin Clin Pharmacokinet 2012 51 147 162 22339447
   PubMed Web of Science ®Google Scholar
• Pratley RE Rosenstock J Pi-Sunyer FX Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy Diabetes Care 2007 30 3017 3022 17878242
   PubMed Web of Science ®Google Scholar
• Baetta R Corsini A Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences Drugs 2011 71 1441 1467 21812507
   PubMed Web of Science ®Google Scholar
• Guarino E Nigi L Patti A Fondelli C Dotta F Combination therapy with metformin plus vildagliptin in type 2 diabetes mellitus Expert Opin Pharmacother 2012 13 1377 1384 22397507
   PubMed Web of Science ®Google Scholar
• Schweizer A Dejager S Foley JE Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin Diabetes Ther 2012 3 8 22736406
   PubMedGoogle Scholar
• Foley JE Bunck MC Möller-Goede DL Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial Diabetologia 2011 54 1985 1991 21547496
   PubMed Web of Science ®Google Scholar
• Monami M Lamanna C Desideri CM Mannucci E DPP-4 inhibitors and lipids: systematic review and meta-analysis Adv Ther 2012 29 14 25 22215383
   PubMed Web of Science ®Google Scholar
• Cai L Cai Y Lu ZJ Zhang Y Liu P The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials J Clin Pharm Ther 2012 37 386 398 22191695
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC Marre M Barzilai N Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency Diabetes Care Epub 12 17 2012
   Web of Science ®Google Scholar
• Nowicki M Rychlik I Haller H Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study Int J Clin Pract 2011 65 1230 1239 21977965
   PubMed Web of Science ®Google Scholar
• Banerji MA Purkayastha D Francis BH Safety and tolerability of vildagliptin vs thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study Diabetes Res Clin Pract 2010 90 182 190 20655609
   PubMed Web of Science ®Google Scholar
• Schweizer A Dejager S Bosi E Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial Diabetes Obes Metab 2009 11 804 812 19476473
   PubMed Web of Science ®Google Scholar
• Ligueros-Saylan M Foley JE Schweizer A Couturier A Kothny W An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of Phase II and III clinical trials Diabetes Obes Metab 2010 12 495 509 20518805
   PubMed Web of Science ®Google Scholar
• Schweizer A Dejager S Foley JE Shao Q Kothny W Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population ≥ 75 years: a pooled analysis from a database of clinical trials Diabetes Obes Metab 2011 13 55 64 21114604
   PubMed Web of Science ®Google Scholar
• Lukashevich V Schweizer A Shao Q Groop PH Kothny W Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial Diabetes Obes Metab 2011 13 947 954 21733061
   PubMed Web of Science ®Google Scholar
• Farngren J Persson M Schweizer A Foley JE Ahrén B Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes J Clin Endocrinol Metab 2012 97 3799 3806 22855332
   PubMed Web of Science ®Google Scholar
• Schweizer A Dejager S Foley JE Couturier A Ligueros-Saylan M Kothny W Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population Diabetes Obes Metab 2010 12 485 494 20518804
   PubMed Web of Science ®Google Scholar
• Kothny W Shao Q Groop PH Lukashevich V One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment Diabetes Obes Metab 2012 14 1032 1039 22690943
   PubMed Web of Science ®Google Scholar
• Christensen M Vedtofte L Holst JJ Vilsbøll T Knop FK Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans Diabetes 2011 60 3103 3109 21984584
   PubMed Web of Science ®Google Scholar
• Ito M Abe M Okada K The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis Endocr J 2011 58 979 987 21921362
   PubMed Web of Science ®Google Scholar
• Nakata H Sugitani S Yamaji S Pancreatitis with pancreatic tail swelling associated with incretin-based therapies detected radiologically in two cases of diabetic patients with end-stage renal disease Intern Med 2012 51 3045 3049 23124148
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC Corry D Mogensen CE Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial Am J Kidney Dis Epub 1 23 2013
   Web of Science ®Google Scholar
• Jin HY Liu WJ Park JH Baek HS Park TS Effect of dipeptidyl peptidase-IV (DPP-IV) inhibitor (Vildagliptin) on peripheral nerves in streptozotocin-induced diabetic rats Arch Med Res 2009 40 536 544 20082866
   PubMed Web of Science ®Google Scholar
• Gonçalves A Leal E Paiva A Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model Diabetes Obes Metab 2012 14 454 463 22151893
   PubMed Web of Science ®Google Scholar
• Ojima A Ishibashi Y Matsui T Glucagon-like Peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression Am J Pathol 2013 182 132 141 23159951
   PubMed Web of Science ®Google Scholar
• Li W Cui M Wei Y Kong X Tang L Xu D Inhibition of the expression of TGF-ß1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist Cell Physiol Biochem 2012 30 749 757 22890152
   PubMed Web of Science ®Google Scholar
• Hocher B Reichetzeder C Alter ML Renal and cardiac effects of DPP-4 inhibitors – from preclinical development to clinical research Kidney Blood Press Res 2012 36 65 84 22947920
   PubMed Web of Science ®Google Scholar
• Liu WJ Xie SH Liu YN Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats J Pharmacol Exp Ther 2012 340 248 255 22025647
   PubMed Web of Science ®Google Scholar
• Vaghasiya J Sheth N Bhalodia Y Manek R Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes Regul Pept 2011 166 48 54 20728477
   PubMedGoogle Scholar
• Glorie LL Verhulst A Matheeussen V DPP-4 inhibition improves functional outcome after renal ischemia-reperfusion injury Am J Physiol Renal Physiol 2012 303 F681 F688 22718884
   PubMed Web of Science ®Google Scholar
• Wang Y Landheer S van Gilst WH Attenuation of renovascular damage in Zucker diabetic fatty rat by NWT-03, an egg protein hydrolysate with ACE- and DPP4-inhibitory Activity PLoS One 2012 7 e46781 23071636
   PubMed Web of Science ®Google Scholar
• Groop P-H Cooper M Perkovic V Effects of the DPP-4 inhibitor linagliptin on albuminuria in patients with type 2 diabetes and diabetic nephropathy Diabetologia 2012 55 Suppl 1 S20 A36
   Google Scholar
• Hung AM Roumie CL Greevy RA Comparative effectiveness of incident oral antidiabetic drugs on kidney function Kidney Int 2012 81 698 706 22258320
   PubMed Web of Science ®Google Scholar
• Panchapakesan U Mather A Pollock C Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease Clin Sci (Lond) 2013 124 17 26 22963445
   PubMed Web of Science ®Google Scholar